Comparative Pharmacology
Head-to-head clinical analysis: GEFITINIB versus VITRAKVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEFITINIB versus VITRAKVI.
GEFITINIB vs VITRAKVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor; inhibits EGFR autophosphorylation and downstream signaling, leading to cell cycle arrest and apoptosis in EGFR-overexpressing tumors.
Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRK) A, B, and C. It binds to the ATP-binding site of TRK kinases, preventing their activation and downstream signaling pathways, thereby inhibiting proliferation and inducing apoptosis in tumors with NTRK gene fusions.
250 mg orally once daily
100 mg orally twice daily
None Documented
None Documented
Terminal half-life 48 hours (range 24-85 hr); supports once-daily dosing, steady state achieved by day 7-10
Clinical Note
moderateGefitinib + Digoxin
"Gefitinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGefitinib + Digitoxin
"Gefitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGefitinib + Deslanoside
"Gefitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGefitinib + Acetyldigitoxin
"Gefitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 16.2 hours (range 12-20 h) in patients; supports twice-daily dosing.
Primarily fecal (86% unchanged + metabolites), renal excretion <5%
Primarily hepatic metabolism, with 39% recovered in feces (36% as unchanged drug) and 18% in urine (0.5% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor